Guest host Cassie Kline, MD, MAS, presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating clinically meaningful endpoints into future trials, as they may better reflect real-world patient benefit than radiographic criteria alone. Dr Kline is a pediatric neuro-oncologist at the Children's Hospital of Philadelphia and is the director of clinical research for the pediatric neuro-oncology group. 

Ver todos los episodios